Pharmaceuticals: A lot to say about BMS Q4 results for European companies
Yesterday BMS released its fourth quarter numbers with an interesting read-across to several European companies in terms of product performance. Plavix and Avapro of course are interesting to observe although less than before; Sprycel (for Novartis’s CML franchise), the Onglyza family (for AstraZeneca as a partner and Novartis as a competitor), Erbitux (for Merck KGaA) and Yervoy (for Roche’s Zelboraf) also give food for thought. It is too early to drive any conclusion about Eliquis.
Please contact firstname.lastname@example.org